NTRA - Natera and Genentech initiate late-stage muscle-invasive bladder cancer trial

Natera (NTRA) announces that the first patient has been screened in a new phase III trial that uses its tumor-informed, personalized molecular residual disease ((MRD)) test, Signatera, as a companion diagnostic to identify muscle-invasive urothelial carcinoma ((MIUC)) patients eligible for investigational treatment with Genentech's, a member of the Roche group (RHHBY), cancer immunotherapy drug atezolizumab (Tecentriq).The IMvigor011 study, sponsored by Genentech, is a global, randomized, placebo-controlled, phase III clinical trial to evaluate the safety and efficacy of adjuvant treatment with the PD-L1 inhibitor, atezolizumab, in patients with MIUC who are MRD-positive after surgery. Eligible patients will be screened with Signatera within the first 20 weeks after surgery, and the first ~500 patients who test MRD-positive will be enrolled and randomized to receive either atezolizumab or placebo for 12 cycles, or up to one year. The primary endpoint of the study will be disease-free survival.In an exploratory analysis from the phase III, randomized,

For further details see:

Natera and Genentech initiate late-stage muscle-invasive bladder cancer trial